Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21304097rdf:typepubmed:Citationlld:pubmed
pubmed-article:21304097lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0155626lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0026565lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0233820lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C1948041lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0522523lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0205421lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:21304097lifeskim:mentionsumls-concept:C1174136lld:lifeskim
pubmed-article:21304097pubmed:issue2lld:pubmed
pubmed-article:21304097pubmed:dateCreated2011-3-16lld:pubmed
pubmed-article:21304097pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:abstractTextPrior studies demonstrate a direct relationship between treatment delays to primary percutaneous intervention and mortality in patients with ST-segment elevation myocardial infarction (STEMI). This analysis compared the relationship of symptom onset-to-balloon time and door-to-balloon time on mortality in patients with STEMI.lld:pubmed
pubmed-article:21304097pubmed:languageenglld:pubmed
pubmed-article:21304097pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:citationSubsetIMlld:pubmed
pubmed-article:21304097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21304097pubmed:statusMEDLINElld:pubmed
pubmed-article:21304097pubmed:monthMarlld:pubmed
pubmed-article:21304097pubmed:issn1941-7705lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:ArmstrongPaul...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:GrangerChrist...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:WeaverW...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:HudsonMichael...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:StebbinsAmand...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:MahaffeyKenne...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:HolmesDavidDlld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:AylwardPhilip...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:RuzylloWitold...lld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:WidimskyPetrPlld:pubmed
pubmed-article:21304097pubmed:authorpubmed-author:O'NeilWilliam...lld:pubmed
pubmed-article:21304097pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21304097pubmed:volume4lld:pubmed
pubmed-article:21304097pubmed:ownerNLMlld:pubmed
pubmed-article:21304097pubmed:authorsCompleteYlld:pubmed
pubmed-article:21304097pubmed:pagination183-92lld:pubmed
pubmed-article:21304097pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:meshHeadingpubmed-meshheading:21304097...lld:pubmed
pubmed-article:21304097pubmed:year2011lld:pubmed
pubmed-article:21304097pubmed:articleTitleMortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.lld:pubmed
pubmed-article:21304097pubmed:affiliationHenry Ford Heart & Vascular Institute, Detroit, MI 48202, USA. mhudson1@hfhs.orglld:pubmed
pubmed-article:21304097pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21304097pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:21304097pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed